Principal Financial Group
VERV

Principal Financial Group’s Verve Therapeutics VERV Stock Holding History

Principal Financial Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,649
Closed -$208K – 2467
2024
Q1 		$208K Buy
15,649
+285
+2% +$3.78K ﹤0.01% 2171
2023
Q4 		$214K Sell
15,364
-1,483
-9% -$18.4K ﹤0.01% 2152
2023
Q3 		$223K Buy
16,847
+2,566
+18% +$41.3K ﹤0.01% 2133
2023
Q2 		$268K Buy
14,281
+509
+4% +$8.48K ﹤0.01% 2103
2023
Q1 		$199K Buy
13,772
+1,364
+11% +$26.7K ﹤0.01% 2183
2022
Q4 		$240K Buy
12,408
+1,883
+18% +$49.9K ﹤0.01% 2154
2022
Q3 		$361K Buy
+10,525
New +$336K ﹤0.01% 2032
2022
Q1 		– Sell
-5,740
Closed -$212K – 2603
2021
Q4 		$212K Buy
+5,740
New +$241K ﹤0.01% 2344

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Principal Financial Group's VERV Position: Q2 2024 in Review

Principal Financial Group sold out of Verve Therapeutics (VERV) in Q2 2024, closing a stake of 15,649 shares — an estimated $208K sold.

Principal Financial Group first reported a position in VERV in Q4 2021 and held it in 8 quarters. The position peaked at $361K in Q3 2022. 166 funds tracked by Wall St. Rank hold VERV as of Q2 2024.

  • Principal Financial Group reported no remaining Verve Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Principal Financial Group sold 15,649 Verve Therapeutics shares in Q2 2024, an estimated $208K.
  • Principal Financial Group first reported a position in Verve Therapeutics in Q4 2021 and held it in 8 quarters.
  • Principal Financial Group's Verve Therapeutics position peaked at $361K in Q3 2022.
  • 166 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2024.

Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.